New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
15:03 EDTFRX, ARRYArray BioPharma hires new Chief Scientific Officer, VP of R&D
Array BioPharma (ARRY) announced the appointments of Nicholas Saccomano, Ph.D., as Chief Scientific Officer and Robert Winkler, M.D., as VP of Clinical Research and Development. Saccomano most recently served as Chief Technology Officer at SomaLogic and as Chief Scientific Officer at Bend Research. Winkler most recently served as VP of Global Clinical Development and Operations at Aptalis Pharma, which was recently acquired by Forest Labs (FRX).
News For ARRY;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
11:17 EDTARRYFTC puts conditions on Novartis's proposed acquisition of GSK oncology drugs
According to the FTC, Global pharmaceutical company Novartis (NVS) has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma (ARRY) to settle charges that Novartis’s $16B acquisition of GlaxoSmithKline’s (GSK) portfolio of cancer-treatment drugs would likely be anticompetitive...If the acquisition goes forward as proposed, Novartis would likely delay or terminate development of both its BRAF and MEK inhibitors, as well as the combination product. For that reason, Novartis’s acquisition of GSK’s portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.S. markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use